| Oksana Hamidi, DO | |
|
2001 Inwood Rd, West Campus Building 3, Dallas, TX 75390 | |
| (214) 645-2800 | |
| (214) 645-2828 |
| Full Name | Oksana Hamidi |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 12 Years |
| Location | 2001 Inwood Rd, Dallas, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629331400 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | R6410 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ut Southwestern University Hospital - William P. Clements Jr. | Dallas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Texas Southwestern Medical Center | 0648188250 | 2588 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Brighton Hospital, the second-oldest alcohol and drug treatment provider in North America, has signed a letter of intent to begin a long-term management contract with a Saudi Arabian company to build a 291,000 square-foot, 250 bed addiction treatment facility in Riyadh, to serve the entire Islamic Mideast.
InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.
Most people have heard of the Hippocratic Oath, taken by doctors committed to practicing medicine ethically. What happens though when doctors, those dedicated to healing and preserving life, cross the line and kill?
› Verified 1 days ago
| Entity Name | University Of Texas Southwestern Medical Center At Dallas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972579365 PECOS PAC ID: 0648188250 Enrollment ID: O20031106000792 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Brighton Hospital, the second-oldest alcohol and drug treatment provider in North America, has signed a letter of intent to begin a long-term management contract with a Saudi Arabian company to build a 291,000 square-foot, 250 bed addiction treatment facility in Riyadh, to serve the entire Islamic Mideast.
InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.
Most people have heard of the Hippocratic Oath, taken by doctors committed to practicing medicine ethically. What happens though when doctors, those dedicated to healing and preserving life, cross the line and kill?
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Oksana Hamidi, DO Po Box 845347, Dallas, TX 75284-7208 Ph: (214) 645-2800 | Oksana Hamidi, DO 2001 Inwood Rd, West Campus Building 3, Dallas, TX 75390 Ph: (214) 645-2800 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Brighton Hospital, the second-oldest alcohol and drug treatment provider in North America, has signed a letter of intent to begin a long-term management contract with a Saudi Arabian company to build a 291,000 square-foot, 250 bed addiction treatment facility in Riyadh, to serve the entire Islamic Mideast.
InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.
Most people have heard of the Hippocratic Oath, taken by doctors committed to practicing medicine ethically. What happens though when doctors, those dedicated to healing and preserving life, cross the line and kill?
› Verified 1 days ago
Uma B.r.k Pakkivenkata, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 215, Dallas, TX 75231 Phone: 214-396-4950 Fax: 877-423-5360 | |
Dr. Ariel Marcelo Modrykamien, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3600 Gaston Ave, Wadley Tower, Suite 960, Dallas, TX 75246 Phone: 402-972-6078 | |
Benjamin Seth Martinez, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-3111 Fax: 214-648-5461 | |
Vijaya Mummadi, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 225, Dallas, TX 75231 Phone: 469-646-8880 Fax: 469-646-8884 | |
Dr. Ting-yi Chen, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2800 Fax: 214-645-2808 | |
William Cook Langmade, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1441 N Beckley Ave, Dallas, TX 75203 Phone: 214-947-2306 | |
Dr. Janame J Kottey, MBBS Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 13154 Coit Rd Ste 100, Dallas, TX 75240 Phone: 214-358-2300 Fax: 214-579-6989 |